Fosamax Lawsuit Update: Bernstein Liebhard LLP Notes Nearly 2,600 Claims Alleging Fosamax Femur Fractures, Other Side Effects, Pending in New Jersey State Litigation
Bernstein Liebhard LLP is actively evaluating Fosamax lawsuits on behalf of individuals who allegedly suffered Fosamax femur fractures.
New York, New York (PRWEB) April 14, 2013
Fosamax lawsuits continue to mount in the consolidated litigation currently underway in New Jersey Superior Court, Bernstein Liebhard LLP reports. A total of 2,599 claims alleging the drug caused users to suffer Fosamax femur fractures and other side effects are currently pending in the litigation, according to the latest case list posted on the Court´s website on April 6th. Court documents indicate that the next Monthly Management Conference in the state Fosamax litigation will be held on May 7th. (In re: Fosamax Litigation, No. 282, N.J. Super. Ct)
“We are pleased to see this litigation moving forward. We are currently representing dozens of women who suffered alleged Fosamax femur fractures and other side effects, and continue to receive inquiries from users of this drug. We look forward to more progress in this proceeding,” says Bernstein Liebhard LLP, a nationwide law firm representing the victims of defective drugs and medical devices. The firm is actively filing Fosamax femur fracture lawsuits in the New Jersey Superior Court litigation.
Fosamax Femur Fracture Lawsuits
Fosamax and other bisphosphonates are used to treat bone weakening diseases, including osteoporosis. These medications were the subject of a U.S. Food & Drug Administration (FDA) advisory issued in October 2010, after studies indicated that people taking bisphosphonates for osteoporosis are at risk of suffering atypical femur fractures. The agency advised doctors to be aware of the possible risk associated with Fosamax and similar drugs, and consider periodic reevaluation of the need for continued treatment in patients taking the medications for longer than five years.*
Since the FDA advisory was issued, thousands of Fosamax lawsuits have been filed in state and federal court on behalf of patients who allegedly suffered femur fractures due to long-term use of the drug. In addition to the claims filed in the consolidated Fosamax litigation now underway in New Jersey Superior Court, additional Fosamax femur fracture lawsuits are pending in a multidistrict litigation established in U.S. District Court, District of New Jersey (In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II) – MDL No. 2243). Court documents indicate that more than 850 claims are currently pending in the federal Fosamax litigation, and the first trial in that proceeding is currently underway. (Glynn v. Merck Sharp & Dohme Corp., 3:11- cv-05304, U.S. District Court, District of New Jersey)
Victims of alleged Fosamax femur fractures could be entitled to compensation for medical bills, lost wages, pain and suffering, and other damages. A wealth of information regarding Fosamax femur fracture lawsuits is available by visiting Bernstein Liebhard LLP´s website. To arrange for a free case review, please contact Bernstein Liebhard LLP at (877) 779-1414.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs´ Hot List,” recognizing the top plaintiffs´ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebfosamax-lawsuits/fosamax-femur-fractures/prweb10630486.htm